Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Therapy Clear all
Completed Phase 1 Interventional

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

NCT00000762
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN, rgp120/HIV-1 SF-2, gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 18 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
33
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 8, 2026, 8:38 AM EDT
Terminated Phase 3 Interventional Results available

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

NCT04181762
View directory record Official record
Conditions
Lupus Nephritis
Interventions
secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Fontana, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 8, 2026, 8:38 AM EDT
Recruiting Phase 3 Interventional

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

NCT07218146
View directory record Official record
Conditions
Small-cell Lung Cancer
Interventions
ZL-1310, Investigator's Choice of Therapy
Drug
Lead sponsor
Zai Lab (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
37
States / cities
La Jolla, California • Sacramento, California • Aurora, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Completed No phase listed Observational

Grid Therapy for Tumors of the Head, Neck, Thorax, Abdomen, Pelvis and Extremities.

NCT04549246
View directory record Official record
Conditions
Radiation Therapy Complication, Tumor Neck, Tumor Abdomen
Interventions
Spatially Fractionated Radiation (GRID) Therapy
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 3 Interventional

TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

NCT00254046
View directory record Official record
Conditions
HIV
Interventions
TMC125, Placebo
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
32
States / cities
Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Not applicable Interventional Results available

Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART

NCT01751646
View directory record Official record
Conditions
HIV Infection
Interventions
Vitamin D3 50,000 IU, Vitamin D3 placebo
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 24 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
16
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Not applicable Interventional Results available

Low Intensity Shock Wave Therapy in the Management of Erectile Dysfunction

NCT04136288
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
MoreNova
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia

NCT03214588
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
TAK-831, TAK-831 Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Gainesville, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 2 Interventional Results available

Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia

NCT00759603
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Lenalidomide, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 2 Interventional Results available

Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial

NCT02218203
View directory record Official record
Conditions
Central Neuropathic Pain, Allodynia, Spinal Cord Injury
Interventions
Dextromethorphan, Lidocaine, Placebo (Dextromethorphan), Placebo (Lidocaine)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 8, 2026, 8:38 AM EDT
Not listed Phase 2 Interventional

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

NCT04646603
View directory record Official record
Conditions
COVID-19, ARDS, Human, Stem Cells, Regeneration
Interventions
MRG-001, Placebo
Drug
Lead sponsor
MedRegen LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Sep 8, 2026, 8:38 AM EDT
Not yet recruiting Not applicable Interventional

TENS of Auricular Vagal Nerve for Radiation Necrosis

NCT07680127
View directory record Official record
Conditions
Radiation Necrosis, Cerebral Edema
Interventions
Transcutaneous auricular vagal nerve stimulation (taVNS), Sham
Device
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

NCT03725761
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sacituzumab Govitecan
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
New York, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Terminated Phase 2 Interventional Results available

Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy

NCT03463161
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
Pembrolizumab, Epacadostat
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 3 Interventional Results available

Atrial Flutter Ablation With Contact Therapy Cool Path Ablation System Along With EnSite Velocity Contact System

NCT01401361
View directory record Official record
Conditions
Typical Atrial Flutter
Interventions
Treatment Arm
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Birmingham, Alabama • Denver, Colorado • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 8, 2026, 8:38 AM EDT
Active, not recruiting Not applicable Interventional

Evaluating a Low-Cost Therapeutic Device in Managing Head and Neck Cancer Patients With Radiation-Related Trismus

NCT05671861
View directory record Official record
Conditions
Trismus, Head and Neck Cancer
Interventions
Trismus Device Prototype, Questionnaires, Mobile Application
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 1 Interventional

Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

NCT01170286
View directory record Official record
Conditions
Peanut Allergy
Interventions
Whole peanut extract, Placebo formulation
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
6 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2012 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 2 Interventional

A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec

NCT00250042
View directory record Official record
Conditions
Leukemia, Other, Cancer
Interventions
Gleevec and Arsenic Trioxide
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 1 Interventional

Compare Pharmacokinetic (PK) Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination

NCT01666678
View directory record Official record
Conditions
Therapeutic Equivalence
Interventions
BAY98-7111, Naproxen Sodium (Aleve, BAYH6689), Diphenhydramine HCl
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Sep 8, 2026, 8:38 AM EDT
Not listed Phase 2 Interventional

Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer

NCT04726215
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
[18F]F AraG
Drug
Lead sponsor
CellSight Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Palo Alto, California • Sacramento, California • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 8, 2026, 8:38 AM EDT
Active, not recruiting Not applicable Interventional

The Heart Health After Cardiac Treatment Study

NCT07158515
View directory record Official record
Conditions
Cardiac Rehabilitation
Interventions
Tailored cardiac rehabilitation, Referral to an external cardiac rehabilitation program
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

NCT03914625
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
Interventions
Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Mercaptopurine Oral Suspension, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
365 Days to 31 Years
Enrollment
6,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
201
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Recruiting Not applicable Interventional

PTSD Treatment for Veterans With Serious Mental Illness to Improve Functional Outcomes

NCT05674617
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic; Mental Disorders
Interventions
Written Exposure Therapy, PTSD Education
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Physiologic Monitoring of Antidepressant Treatment Response

NCT00759317
View directory record Official record
Conditions
Depression
Interventions
venlafaxine (Effexor)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Sep 8, 2026, 8:38 AM EDT